Pushing the Limits: Exploring Hyperbaric Oxygen’s Evolving Role Against Relentless Mucormycosis

February 25, 2024

Back
Featured image for “Pushing the Limits: Exploring Hyperbaric Oxygen’s Evolving Role Against Relentless Mucormycosis”

Invasive fungal disease imparts misery and mortality, especially among the immunocompromised. Yet the angioinvasive mold infections collectively deemed mucormycosis progress with particular lethality. Representing global rising threats after COVID-19, these previously rare fungi tolerate many standard interventions poorly. Mortality despite maximized care still exceeds 50% driving innovation necessity. Could age-old hyperbaric oxygen therapy finally move outcomes by tackling root pathophysiology when paired with antifungals and surgery? Science suggests potential – and often in spheres where all other options already failed.

Mucormycosis: A “Perfect Storm” Emerging

Found readily in rotting vegetation, foods and animal waste worldwide, spores from Rhizopus, Mucor, Lichtheimia and other molds in the order Mucorales release easily into air or wounds. Normally dispatched swiftly, spores germinate in those with weakened immunity and dysfunctional metabolism – propagating relentlessly as hosts struggle to rebalance defenses.

Uncontrolled diabetes now most commonly underpins infection. But organ transplant recipients, hematologic and ICU patients also fall vulnerable when usual safeguards falter. Steroids, cancers, injuries and coronaviruses further stack the deck creating a “perfect storm” for mucormycosis invasion unseen previously on today’s scale. Fighting back requires new angles.

55

Hyperbaric Oxygen’s Mechanistic Rationale

Invented over 70 years ago for decompression illness, hyperbaric oxygen therapy (HBOT) utilizes pure oxygen in a pressurized chamber to drive enhanced diffusion into tissues starved of adequate delivery. Through mechanisms only partly elucidated, researchers confirm hyperoxygenation triggers a cascade of beneficial cellular and immune effects in multiple disease states with ischemia playing central pathophysiologic roles.

In mucormycosis, bound oxygen acts as natural antifungal while enabling struggling phagocytes to terminate spores. HBOT further reduces surrounding acidosis and edema that fungi exploit to thrive. The localized environment turn no longer favors such opportunistic pathogens. But clinical translation remains incomplete.

Mucormycosis HBOT Trial Evidence

Data directly measuring HBOT’s impact on mucormycosis outcomes remain surprisingly sparse despite intriguing anti-fungal effects demonstrated with other invasive molds in laboratory experiments. However, case reports and series analysis in rhino-cerebral and pulmonary disease hint at benefit when judiciously combined with antifungal drugs and surgical debridement for refractory infections.

A 2016 literature review across such observational analyses suggested improved survivorship approximating 80% using HBOT versus 40-70% among matched controls – numbers otherwise deemed acceptable in such gravely ill cohorts with central nervous system penetration. Sample sizes stay small however, and controlled trials largely lacking. Yet logic supports further exploration under careful protocols given morbidity and mortality stakes.

Candidate Selection, Timing and Delivery Optimization

Clinical consensus maintains HBOT works best alongside standard medical/surgical mucormycosis treatment as adjunctive – not primary – therapy. Patients should exhibit adequate respiration, hemodynamics and oxygenation before starting sessions. Certain ocular issues may also exclude candidacy temporarily.

However, once eligible and enrolled after informed consent, daily sessions commence delivering 100% oxygen at over two atmospheres pressure for 90-120 minutes with heavy rest and monitoring after given potential arrhythmia risks. Such exposures continue for minimum 30 sessions with infection surveillance guiding any cessation. Concurrent antifungal therapy facilitates eradication.

No universal protocols define session number, blood pressure parameters or additive agents like anticoagulants yet. Careful observation for early decompression sickness signs also remains key throughout treatment courses. But early contributors survive diseases once rapidly fatal.

Weighing Limitations and Future Directions

Like any therapy, HBOT risks complications, costs and inconsistent outcomes. Pulmonary oxygen toxicity, confined space risks, uncertain duration efficacy and access barriers do steer ongoing judiciousness ensuring short and long-term safety. Younger, more physiologically resilient patients tolerate exposures best based on case reports.

However, conceiving combination regimens further leveraging hyperoxygenation looks attractive considering mucormycosis mortality trends. Coupling existing antifungal and surgical care with elevated atmospheric oxygen, iron chelators, selected vasodilators, immunostimulants and nutrition components await study through forthcoming trials that may finally tip the tide favorably. HBOT’s niche role likely secures by enhancing such adjunctive partners.

Investing research here honors patients otherwise facing dismal prognoses despite exhaustive care attempts. Even modest gains positively disrupt traditionally relentless downward trajectories, sparing grievous losses.

57

FAQs on using hyperbaric oxygen therapy for mucormycosis

How does hyperbaric oxygen therapy combat mucormycosis infections?

Hyperbaric oxygen (HBOT) fights mucormycosis through direct antifungal effects at higher atmospheric pressures and by enabling patient immune cells to terminate germinating spores. HBOT also reduces local acidosis and edema that fungi exploit to proliferate in tissues.

What evidence exists supporting hyperbaric oxygen use against mucormycosis?

No large controlled trials yet confirm HBOT’s efficacy against mucormycosis. However, smaller case reports and retrospective data analyses demonstrate improved survival over standard therapy alone when carefully incorporated alongside antifungal medications and surgery in difficult rhino-orbital and pulmonary mucormycosis cases.

How is hyperbaric oxygen therapy administered for mucormycosis treatment?

After screening for eligibility, HBOT is delivered using a specialized chamber with 100% oxygen under 2-3 atmospheres pressure for 60-120 minutes daily. 30-60 total sessions are typical over 30-90 days depending on clinical response, with continued antifungal therapy throughout. Careful monitoring for toxicity is key.

What types of mucormycosis infections are best suited to adjunctive hyperbaric oxygen?

Early data suggests HBOT benefits those over age 12 with refractory rhino-orbital-cerebral or pulmonary mucormycosis despite maximized medical and surgical management. More research is needed to clarify optimal patient selection, but using HBOT on diagonal spread, immunocompromised or treatment-intolerant patients holds promise based on case analyses.

What risks or limitations exist for using hyperbaric oxygen as mucormycosis therapy?

HBOT adverse effects include pressure-related traumas, oxygen toxicity causing lung damage, confined space risks like fire or gas exposures, and uncertain long term impact on treatment efficacy or resistance patterns. Cost, access barriers, patient intolerance, uncertain optimal protocols, and variable survivorship also limit application presently. Further study continues working through such translation gaps.

56

Key Takeaways

  • Mucormycosis outbreaks are deepening globally due to COVID-19 related “perfect storms” of immunosuppression and metabolism dysfunction
  • Standard therapies only suboptimally control invasive fungal infections carrying high mortality
  • Hyperbaric oxygen has demonstrated anti-fungal properties in laboratory studies by enabling struggling leukocytes
  • Clinical reports suggest improved mucormycosis outcomes when carefully incorporating HBOT alongside antifungal medicines and surgery
  • Further research still needed to clarify protocols, partners, duration and ideal patient selection criteria going forward

Until fungicidal medications emerge against these deadly fungi, optimizing host defenses through considered hyperoxygenation looks increasingly worthwhile where dismal outcomes otherwise prevail. The first glimmers of hope emerge.

Rate this post

Related articles



Image
Image

MIRARI®
Cold Plasma System

The world's first handheld cold plasma device

Learn More


Made in USA

Image